Free shipping on all orders over $ 500

KU-60019

Cat. No. M1998

All AbMole products are for research use only, cannot be used for human consumption.

KU-60019 Structure
Size Price Availability Quantity
5mg USD 75 In stock
10mg USD 100 In stock
50mg USD 300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

KU-60019 is a potent ATM kinase inhibitor with IC50 of 6.3 nM. KU-60019 exhibits little to no nonspecific target effects, displaying similar target selectivity to KU 55933. KU-60019 inhibited the phosphorylation of the major DNA damage effectors p53, H2AX and KAP1 as well as AKT. KU-60019 effectively radiosensitizes human glioma cells with dose-enhancement ratio of 1.7 and 4.4 at 1 μM and 10 μM, respectively, and also radiosensitizes the normal fibroblasts but not the A-T fibroblasts. KU-60019 has also been shown to Inhibit invasion and migration of human glioma cells in vitro. KU-60019 is 10-fold more effective than KU-55933 at blocking radiation-induced phosphorylation of key ATM targets in human glioma cells. KU-60019 treatment (3 μM) blocks basal and insulin-induced AKT S473 phosphorylation by 70% and ~50%, respectively, and completely reduces radiation-induced AKT phosphorylation below the level of control.

Product Citations
Customer Product Validations & Biological Datas
Source Med Sci Monit (2017). Figure 4.KU-60019
Method Proliferation assay
Cell Lines PA-SMCs
Concentrations 0.1 μM, 0.3 μM, 0.5 μM
Incubation Time 24 h
Results The results demonstrated that at a concentration of 0.5 μM, KU60019 increased cell growth more noticeably compared with other groups
Chemical Information
Molecular Weight 547.67
Formula C30H33N3O5S
CAS Number 925701-49-1
Solubility (25°C) DMSO 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Golding SE, et al. Cell Cycle. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.

[2] Golding SE, et al. Mol Cancer Ther. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.

Related ATM/ATR Products
KU-55933

KU-55933 is a cell-permeable ATP-competitive inhibitor of ATM (IC50 = 13 nM; Ki = 2.2 nM) with selectivity over other PIKK family kinases (IC50 = 2.5, 9.3, 16.6 μM for DNAPK, mTOR, PI 3-K, respectively; IC50 > 100 μM for PI 4-K and ATR).

VE-821

VE-821 is a highly selective and potent ATR inhibitor with IC50 of 26 nM.

ETP-46464

ETP-46464 is a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-Kα and ATM with IC50 of 0.6, 14, 36, 170 and 545 nM, respectively.

CP-466722

Cp-466722 is a reversible ATM inhibitor with IC50 value of 4.1 μM, but has no effect on PI3K, PIKK family proteins.

AZ20

AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM, 8-fold selectivity over mTOR.

  Catalog
Abmole Inhibitor Catalog




Keywords: KU-60019 supplier, ATM/ATR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.